Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet

Dow Jones04-03

By Ben Glickman

Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours.

Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading.

OneMedNet said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

April 02, 2024 19:39 ET (23:39 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424888299?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 07:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424888299","market":"other","top_or_hot":-1,"title":"Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours. \n</p>\n<p>\n  Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/ONMD\">OneMedNet</a> said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2024 19:39 ET (23:39 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Intel, Vanda Pharmaceuticals, OneMedNet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4529","symbol_name":"IDC概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2424888299","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424888299","pubTimestamp":1712101140,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours.Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading.OneMedNet said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4529":"IDC概念","INTC":"英特尔","BK4554":"元宇宙及AR概念","BK4515":"5G概念","ONMD":"OneMedNet","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4575":"芯片概念","BK4535":"淡马锡持仓","BK4167":"医疗保健技术","BK4527":"明星科技股","VNDA":"万达生物制药","BK4579":"人工智能","BK4550":"红杉资本持仓","BK4588":"碎股","BK4141":"半导体产品","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4512":"苹果概念"},"translate_title":"值得关注的股票：英特尔、中联制药、OneMedNet","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNDA":1,"ONMD":1,"INTC":1},"content_text":"By Ben Glickman \n\n\n \n\n\n  Intel released restated results for the last three years to break out its foundry business, revealing the segment generated an operating loss of about $7 billion in 2023. The business's sales from other parts of Intel, or internal revenue, fell sharply to $18 billion that same year. Shares fell 3.8%, to $42.26, after hours. \n\n\n  Vanda Pharmaceuticals said it had received regulatory approval for Fanapt to treat manic or mixed episodes linked to bipolar I disorder in adults. The treatment has been used in adults with schizophrenia for years, but the company said the new indication would increase Fanapt's commercial opportunity. Shares surged 31%, to $5.13, in late trading. \n\n\nOneMedNet said it had secured up to $4.54 million in cash through a securities purchase agreement with an institutional investor. The company also announced Aaron Green as its next chief executive as predecessor Paul Casey retires. Shares rose 44%, to $1.14, in the post-market session. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2024 19:39 ET (23:39 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424888299"}